Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

Exclusion Criteria

• •Non-English speaking
• •Antenatal suspicion for placenta accreta spectrum
• •History of allergic reaction to Calcium Gluconate
• •Patients with hypertensive disorder of pregnancy receiving Magnesium Sulfate for seizure prophylaxis
• •Underlying Renal Disease defined as Cr\>1.0
• •Known underlying cardiac condition
• •Cardiac glycosides (Digoxin) within two weeks for maternal or fetal indication
• •Treatment with a calcium channel blocker medication within 24 hours of screening
• •Hypertensive disorder necessitating intravenous antihypertensive medication within 24 hours of screening
• •Emergent case where study participation could impede care (judgement of obstetrician or anesthesiologist)
• •Known hypercalcemia
• •Concurrent use of any drugs that may cause hypercalcemia including
• •1. Vitamin D
• •2. Vitamin A
• •3. Thiazide Diuretics
• •4. Calcipotriene
• •5. Teriparatide
• •Ceftriaxone within 48 hours of screening
• •Total Parenteral Nutrition (TPN) within 48 hours of screening
• •Known Coagulopathy International Normalized Ratio (INR) ≥ 1.5
• •Vaginal delivery